Acute liver failure (ALF) is one of the most time-critical syndromes in hepatology. It is rare and potentially reversible but carries high short-term mortality when recognition and management are delayed. The window for intervention is narrow, and early involvement of a transplant center is essential.
Here are five concepts that sharpen the approach to this challenging syndrome.
1. Definition Is the Diagnosis
ALF is defined as acute liver injury with impaired synthetic function (international normalized ratio [INR] ≥ 1.5) and hepatic encephalopathy in a patient without preexisting cirrhosis or chronic liver disease. The absence of prior liver disease distinguishes ALF from acute decompensation of chronic liver disease and carries distinct prognostic and management implications.
The European Association for the Study of the Liver further distinguishes acute liver injury (coagulopathy without encephalopathy) from ALF, recognizing that progression between the two can be rapid and clinically unforgiving.
Early imaging in ALF may appear cirrhotic. A necrotic but regenerating liver can take on a nodular appearance on ultrasound or cross-sectional imaging, potentially misleading clinicians into attributing the presentation to chronic liver disease and delaying appropriate triage. In the right clinical context (no prior liver history, rising INR, and encephalopathy), imaging findings should not override clinical criteria.
2. Etiology Cannot Wait
ALF is a syndrome rather than a single disease, and etiology guides treatment. Cause-specific interventions must be initiated within hours, not after a full workup is complete.
The American College of Gastroenterology’s ALF guidelines emphasize immediate evaluation for acetaminophen toxicity, acute viral hepatitis (A, B, and E in appropriate epidemiologic contexts), autoimmune hepatitis, ischemic hepatitis, drug-induced liver injury, Wilson disease, Budd-Chiari syndrome, and pregnancy-related liver disease — including acute fatty liver of pregnancy and hemolysis, elevated liver enzymes, low platelet syndrome.
Two patterns warrant immediate action. First, obtain an acetaminophen level in every patient, even when the history doesn’t suggest exposure. Intentional overdose is often underreported, and acetaminophen toxicity remains the most common cause of ALF in the US, as well as the most immediately actionable.
Second, a disproportionately low alkaline phosphatase relative to bilirubinshould prompt immediate consideration of Wilson disease, a treatable but easily missed etiology that carries a poor prognosis without rapid intervention.
Once ALF is suspected, early transplant-center involvement should occur in parallel with ICU stabilization.
3. Cerebral Edema and the Race Against Herniation
Neurologic deterioration is what makes ALF uniquely lethal and distinguishes it from other liver syndromes. Unlike encephalopathy in chronic cirrhosis, where the brain adapts gradually over months to years of ammonia exposure, the brain in ALF has no such accommodation. Hyperammonemia, combined with systemic neuroinflammation, creates conditions for cerebral edema and, in severe cases, uncal herniation.
ICU-level monitoring is warranted as soon as ALF is suspected, not after encephalopathy progresses. Ammonia levels, although imperfect, are a clinically useful gauge of herniation risk in this setting. Higher levels are associated with substantially increased risk.
Early ammonia reduction should be prioritized. Continuous renal replacement therapy may be used even in the absence of conventional renal indications. Supportive osmotic therapy, infection vigilance, and avoidance of oversedation are critical. Intracranial pressure monitoring may be considered an option at centers with appropriate expertise.
4. N-acetylcysteine (NAC)
NAC remains the definitive treatment for acetaminophen-induced ALF, with intravenous administration as the standard of care regardless of time since ingestion.
The more pressing question is whether NAC benefits non-acetaminophen ALF. Evidence is mixed, with no consistent mortality benefit demonstrated across studies. However, NAC is frequently initiated early while etiology is being clarified.
NAC is a low-risk intervention with a plausible antioxidant mechanism. In practice, the rationale for early initiation is less about definitive benefit and more about the imperative to act during the critical workup period. NAC should not delay or replace transplant evaluation.
5. Emerging Role of Plasma Exchange
High-volume plasma exchange (HVP) has re-emerged as a potential bridge strategy in ALF management, with increasingly supportive evidence. Recent meta-analyses suggest improved short-term survival, including in single-etiology cohorts.
The proposed benefit lies in attenuation of innate immune activation and reduction in multi-organ dysfunction.
Key clinical questions remain regarding optimal volume, timing, and patient selection. Nonetheless, HVP may serve as a bridge, either to spontaneous hepatic recovery or to transplantation in eligible patients when recovery does not occur.
Summary
ALF is defined by its rapid onset, swift deterioration, and the urgency of decision-making it demands. Etiology-specific treatment, early neuroprotective management, and appropriate use of NAC and plasma exchange are critical components of care that separate recoverable outcomes from catastrophic ones. Even with optimal management, ALF leaves little margin for delay.